Clinical Trials
7
Active:2
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 1
3 (42.9%)Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
Phase 2
Not yet recruiting
- Conditions
- Diabetic Kidney Disease (DKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT06962098
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
Phase 2
Recruiting
- Conditions
- Contrast Induced Acute Kidney Injury
- Interventions
- Drug: PlaceboDrug: Isuzinaxib (APX-115)
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT05758896
- Locations
- 🇺🇸
Florida Cardiovascular Research, Hialeah, Florida, United States
🇺🇸Sarkis Clinical Trials, Ocala, Florida, United States
🇰🇷Kangwon National University Hospital, Chuncheon, Korea, Republic of
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04880109
- Locations
- 🇺🇸
Alternative Research Associates, LLC, Hialeah, Florida, United States
🇺🇸Anne Arundel Medical Center, Baltimore, Maryland, United States
🇺🇸Millennium Physicians Group, Houston, Texas, United States
Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
Phase 2
Completed
- Conditions
- Nephropathy, DiabeticDiabetic NephropathiesDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04534439
- Locations
- 🇧🇬
Pleven, Pleven, Bulgaria
🇧🇬Sveta Karidad, Plovdiv, Bulgaria
🇧🇬Diagnostic-consultative centre I, Sliven, Bulgaria
Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- SafetyHealthy
- Interventions
- Other: Metabolic probe with or without APX-115
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Aptabio Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT03694041
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
News
No news found